“We are looking forward to an active 2016, that, in addition to the Epidiolex Phase 3 data, is expected to include our first NDA filing, expansion of our U.S. commercial organization, and ongoing data readouts from a number of clinical pipeline programs.” NDA submission with FDA expected Q4 2016.